Skip to search formSkip to main contentSkip to account menu

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

CisplatinDrug CombinationsGlutathione Disulfide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… 
Review
2011
Review
2011
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
The vulnerability of some cancer cells to oxidative signals is a therapeutic target for the rational design of new anticancer… 
2010
2010
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung…
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance… 
2010
2010
Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity.
2009
2009
Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and…
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2141 Background: Chemotherapy induced anemia is a… 
2009
2009
Pharmacology of a mimetic of glutathione disulfide, NOV-002.
  • D. TownsendK. Tew
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2009
  • Corpus ID: 15437674
Review
2008
Review
2008
NOV-002, a mimetic of glutathione disulfide
Background: Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new… 
2008
2008
NOV-002 plus carboplatin in platinum-resistant ovarian cancer
5593 Background: Platinum remains the single most effective drug for the treatment of epithelial ovarian cancer; however with… 
2006
2006
NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): A randomized Phase 1/2, open-label, controlled study.
17021 Background: NOV-002 is a proprietary formulation of oxidized glutathione that modulates production of cytokines and… 
Review
2005
Review
2005
Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)